High-dose of potent statins may not be sufficient to achieve therapeutic goals of ldlc and non-hdl cholesterol in patients at very high cardiovascular risk

Casarini, Giseli; Donadon, Natan Alevato; Pacheco, Gabriel Tamanaha; Bringel, Rafael Ferreira e; Domingos, Sara Regina Alcalde; Faludi, André Árpád; Araujo, Daniel Branco de; Santos, Natasha Soares Simões dos; Bertolami, Adriana; Schmidt, Luiz Paulo Bastos.
Arq. bras. cardiol ; 119(4 supl.1): 165-165, Oct, 2022.
Artigo Inglês | CONASS, SES-SP, SES SP - Instituto Dante Pazzanese de Cardiologia, SES-SP | ID: biblio-1397313

Documentos relacionados

  1. Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease.
  2. Evaluation of the apolipoprotein E (apoE)-HDL-associated risk factors for coronary heart disease using duo-functional electrochemical aptasensor.
  3. The Present and Future of Lipid Testing in Cardiovascular Risk Assessment.
  4. Regular exercise and patterns of response across multiple cardiometabolic traits: the HERITAGE family study.
  5. Platelets as Potential Non-Traditional Cardiovascular Risk Factor-Analysis Performed in Healthy Donors.
  6. Association between sleep duration and cardiometabolic factors in adolescents.
  7. [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe - data from the SANTORINI registry].
  8. Asking informed consent may lead to significant participation bias and suboptimal cardiovascular risk management in learning healthcare systems.
  9. Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial.
  10. MAFLD is associated with increased all-cause mortality in low cardiovascular-risk individuals but not in intermediate to high-risk individuals.